The global anti depression drugs market is expected to reach a valuation at USD 17.1 billion by 2027 and from USD 14.9 billion in 2020 with a CAGR of 2.0% over the forecast period. The driving factors influencing the global anti depression market include the growing prevalence of depression, emergence of techniques for the development of drugs with minimum side-effects. Another driving factor influencing the global anti depression market includes a growing population suffering from stress, rising concerns in awareness about the disease state and required clinical needs.
With the poor efficacy and safety profiles of the drug, increasing number of patient expiration, and preference for non-pharmacological therapies, and increasing count of deaths due to stress, the demand for the global anti depression market is anticipated to hamper the growth over the forecast period.
Anti depression drugs are generally used for the treatment of depressive disorders including chronic pain, obsessive compulsive disorder, dysthymia, anxiety, eating disorders, and neuropathic pain. Depression is a disorder which is related to the brain and it happens due to the increasing stress level, improper routine, unhealthy diet, minimum hours of sleep, and more. Moreover, the symptoms of depression include reduced energy, feeling emotionally sad, and difficulty in enjoying routine activities.
Most of the leading players are looking forward to expanding their distribution network with an intention to promote their businesses and increase the graphs of profit margins. Moreover, the emerging nations such as the Middle East & Africa, Asia Pacific, and Latin America are on the verge to increase prevalence of various types of depressive disorders and improving economic conditions. With the growing differences in clinical efficacy and drugs, most of the modern antidepressants work through common biological mechanisms.
According to the CDC, depression is often seen in the people in the United States. In line to the World Health Organization, over 350 million people have been expected to go through depression disorder. Depression affects over 10% to 15% men and about 10% to 25% of women.
The global anti depression market is categorized into several segmentations including depression disorder overview, product overview, and regions. Based on the depression disorder overview, the global anti depression market is fragmented into Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Major Depressive Disorder, and Others. Based on the product type overview, the global anti depression market is segregated into Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine oxidase inhibitors, Serotonin antagonist, reuptake inhibitors, Serotonin-norepinephrine reuptake Inhibitors, and Others. The depression disorder type segment is about to project faster growth along with tremendous popularity in the market owing to a growing population suffering from stress, rising concerns in awareness about the disease state and required clinical needs. This boosts the demand for the global anti depression market with a tremendous growth over the forecast period.
Based on region, the global anti depression market is widespread to the Middle East and Africa, Egypt, Saudi Arabia, Canada, South Africa, Asia Pacific, Argentina, Mexico, Korea, India, France, Turkey, Nigeria, UAE, Europe, Japan, China, UK, Russia, South America, Brazil, Italy, North America, Southeast Asia, Germany, USA, and Columbia.
North America is anticipated to hold the largest market size in the global anti depression market, followed by Europe. This is due to the increasing presence of key vendors in the region. Furthermore, Europe is expected to hold the highest market size in the market resulting in GDPR compliance. Due to the increasing technological advancement in Asia Pacific region, the factors influencing the anti depression market include growing prevalence of depression, emergence of novel techniques for the development of drugs with fewer side-effects, and rising geriatric population.
In terms of market players, the global anti depression market is competitive and fragmented with the presence of various kind of different vendors including Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Bristol Myers Squibb Co., Opko Health, Novartis, Forest Laboratories, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Alkermes Plc, and AstraZeneca.
With the poor efficacy and safety profiles of the drug, increasing number of patient expiration, and preference for non-pharmacological therapies, and increasing count of deaths due to stress, the demand for the global anti depression market is anticipated to hamper the growth over the forecast period.
Anti depression drugs are generally used for the treatment of depressive disorders including chronic pain, obsessive compulsive disorder, dysthymia, anxiety, eating disorders, and neuropathic pain. Depression is a disorder which is related to the brain and it happens due to the increasing stress level, improper routine, unhealthy diet, minimum hours of sleep, and more. Moreover, the symptoms of depression include reduced energy, feeling emotionally sad, and difficulty in enjoying routine activities.
Most of the leading players are looking forward to expanding their distribution network with an intention to promote their businesses and increase the graphs of profit margins. Moreover, the emerging nations such as the Middle East & Africa, Asia Pacific, and Latin America are on the verge to increase prevalence of various types of depressive disorders and improving economic conditions. With the growing differences in clinical efficacy and drugs, most of the modern antidepressants work through common biological mechanisms.
According to the CDC, depression is often seen in the people in the United States. In line to the World Health Organization, over 350 million people have been expected to go through depression disorder. Depression affects over 10% to 15% men and about 10% to 25% of women.
The global anti depression market is categorized into several segmentations including depression disorder overview, product overview, and regions. Based on the depression disorder overview, the global anti depression market is fragmented into Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Major Depressive Disorder, and Others. Based on the product type overview, the global anti depression market is segregated into Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine oxidase inhibitors, Serotonin antagonist, reuptake inhibitors, Serotonin-norepinephrine reuptake Inhibitors, and Others. The depression disorder type segment is about to project faster growth along with tremendous popularity in the market owing to a growing population suffering from stress, rising concerns in awareness about the disease state and required clinical needs. This boosts the demand for the global anti depression market with a tremendous growth over the forecast period.
Based on region, the global anti depression market is widespread to the Middle East and Africa, Egypt, Saudi Arabia, Canada, South Africa, Asia Pacific, Argentina, Mexico, Korea, India, France, Turkey, Nigeria, UAE, Europe, Japan, China, UK, Russia, South America, Brazil, Italy, North America, Southeast Asia, Germany, USA, and Columbia.
North America is anticipated to hold the largest market size in the global anti depression market, followed by Europe. This is due to the increasing presence of key vendors in the region. Furthermore, Europe is expected to hold the highest market size in the market resulting in GDPR compliance. Due to the increasing technological advancement in Asia Pacific region, the factors influencing the anti depression market include growing prevalence of depression, emergence of novel techniques for the development of drugs with fewer side-effects, and rising geriatric population.
In terms of market players, the global anti depression market is competitive and fragmented with the presence of various kind of different vendors including Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc, Bristol Myers Squibb Co., Opko Health, Novartis, Forest Laboratories, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Alkermes Plc, and AstraZeneca.
- Aerospace and Defense
- Agriculture
- Automotive and Transportation
- Business and Finance
- Chemical and Materials
- Consumer Goods and Retails
- Electronics and Semiconductor
- Energy and Power
- Food and Beverages
- Machinery and Equipment
- Manufacturing and Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Service and Software
- Technology, Media and Telecommunications
- Travel and Tourism
